Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2028-08-19
Target enrollment:
Participant gender:
Summary
This study will examine the safety of three times weekly SC injections of OPT101 at each of three dose levels over two weeks as well as one year of treatment with SC OPT101 or placebo to match at a single dose level.